— Know what they know.
Not Investment Advice

CEMI NASDAQ

Chembio Diagnostics, Inc.
1W: +1.1% 1M: +16.4% 3M: +30.0% 1Y: -27.4% 3Y: -96.5% 5Y: -94.2%
$0.46
Last traded 2023-04-27 — delisted
NASDAQ · Healthcare · Medical - Diagnostics & Research · $16.7M mcap · 31M float · 1.74% daily turnover

Balance Sheet Trends

Total Assets
$63M -14.5% ▼
5Y CAGR: +30.4%
Total Liabilities
$45M +14.9% ▲
5Y CAGR: +66.2%
Shareholders Equity
$18M -48.1% ▼
5Y CAGR: +6.4%
Cash & Investments
$18M -36.8% ▼
5Y CAGR: +36.8%
Total Debt
$25M -3.0% ▼
5Y CAGR: +202.2%
Net Debt
$7M +336.9% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2018FY2019FY2020FY2021FY2022
— Assets —
Cash$13M$18M$23M$29M$18M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$13M$18M$23M$29M$18M
Net Receivables$7M$4M$3M$11M$19M
Inventory$8M$10M$13M$13M$8M
Other Current Assets$702K$693K$779K$2M$4M
Total Current Assets$28M$32M$40M$55M$48M
Property, Plant & Equip.$3M$13M$15M$15M$14M
Goodwill & Intangibles$9M$10M$10M$3M$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$718K$544K$509K$744K$435K
Total Non-Current Assets$12M$24M$25M$18M$14M
Total Assets$41M$56M$65M$73M$63M
— Liabilities —
Accounts Payable$4M$3M$6M$8M$3M
Short-Term Debt$208K$790K$701K$2M$20M
Deferred Revenue$423K$125K$2M$0$0
Other Current Liabilities$2M$2M$4M$5M$16M
Total Current Liabilities$7M$6M$12M$15M$39M
Long-Term Debt$172K$25M$25M$24M$6M
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$1M$25M$25M$24M$6M
Total Liabilities$8M$32M$37M$39M$45M
— Equity —
Common Stock$172K$177K$202K$301K$368K
Retained Earnings-$58M-$72M-$97M-$131M-$154M
Accumulated OCI$112K$10K-$91K-$592K-$337K
Total Stockholders Equity$33M$24M$28M$34M$18M
Total Liabilities & Equity$41M$56M$65M$73M$63M
— Key Metrics —
Total Debt$380K$26M$25M$26M$25M
Net Debt-$12M$7M$2M-$3M$7M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms